Literature DB >> 28392558

The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.

Richard P Junghans1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28392558     DOI： 10.1038/cgt.2016.82

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


× No keyword cloud information.
  116 in total

1.  Specificity for molecules of the major histocompatibility complex mediated by a hybrid immunoglobulin-T cell receptor.

Authors:  H Kawasaki; M L Becker; S M Hedrick
Journal:  New Biol       Date:  1991-05

2.  Protection against melanoma by vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control.

Authors:  Bernd Krone; Klaus F Kölmel; Beate M Henz; John M Grange
Journal:  Eur J Cancer       Date:  2005-01       Impact factor: 9.162

3.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

4.  T-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters.

Authors:  Boryana N Manz; Bryan L Jackson; Rebecca S Petit; Michael L Dustin; Jay Groves
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

5.  T-cell immunotherapy: looking forward.

Authors:  Jacqueline Corrigan-Curay; Hans-Peter Kiem; David Baltimore; Marina O'Reilly; Renier J Brentjens; Laurence Cooper; Stephen Forman; Stephen Gottschalk; Philip Greenberg; Richard Junghans; Helen Heslop; Michael Jensen; Crystal Mackall; Carl June; Oliver Press; Daniel Powell; Antoni Ribas; Steven Rosenberg; Michel Sadelain; Brian Till; Amy P Patterson; Robert C Jambou; Eugene Rosenthal; Linda Gargiulo; Maureen Montgomery; Donald B Kohn
Journal:  Mol Ther       Date:  2014-09       Impact factor: 11.454

6.  The law of mass action governs antigen-stimulated cytolytic activity of CD8+ cytotoxic T lymphocytes.

Authors:  Y Sykulev; R J Cohen; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

Review 7.  Locoregional immuno(bio)therapy for liver metastases.

Authors:  Takami Sato
Journal:  Semin Oncol       Date:  2002-04       Impact factor: 4.929

8.  Successful treatment of melanoma brain metastases with adoptive cell therapy.

Authors:  Jenny J Hong; Steven A Rosenberg; Mark E Dudley; James C Yang; Donald E White; John A Butman; Richard M Sherry
Journal:  Clin Cancer Res       Date:  2010-08-18       Impact factor: 12.531

9.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

Review 10.  Spontaneous regression of metastases from melanoma: review of the literature.

Authors:  Louise Vennegaard Kalialis; Krzysztof T Drzewiecki; Helle Klyver
Journal:  Melanoma Res       Date:  2009-10       Impact factor: 3.599
View more
  7 in total

1.  Assessment of chimeric antigen receptor T cytotoxicity by droplet microfluidics in vitro.

Authors:  Kuan Un Wong; Jingxuan Shi; Peng Li; Haitao Wang; Yanwei Jia; Chuxia Deng; Lianmei Jiang; Ada Hang-Heng Wong
Journal:  Antib Ther       Date:  2022-03-24

2.  Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches.

Authors:  Hwai Wen Chang; Gerhard Frey; Haizhen Liu; Charles Xing; Lawrence Steinman; William J Boyle; Jay M Short
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

3.  YY1 Upregulates Checkpoint Receptors and Downregulates Type I Cytokines in Exhausted, Chronically Stimulated Human T Cells.

Authors:  Mumtaz Y Balkhi; Gabor Wittmann; Fang Xiong; Richard P Junghans
Journal:  iScience       Date:  2018-04-11

4.  Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.

Authors:  Yogindra Vedvyas; Jaclyn E McCloskey; Yanping Yang; Irene M Min; Thomas J Fahey; Rasa Zarnegar; Yen-Michael S Hsu; Jing-Mei Hsu; Koen Van Besien; Ian Gaudet; Ping Law; Nak Joon Kim; Eric von Hofe; Moonsoo M Jin
Journal:  Sci Rep       Date:  2019-07-23       Impact factor: 4.379

Review 5.  Receptor signaling, transcriptional, and metabolic regulation of T cell exhaustion.

Authors:  Mumtaz Y Balkhi
Journal:  Oncoimmunology       Date:  2020-04-14       Impact factor: 8.110

6.  Antigen Specificity Enhances Disease Control by Tregs in Vitiligo.

Authors:  Zhussipbek Mukhatayev; Emilia R Dellacecca; Cormac Cosgrove; Rohan Shivde; Dinesh Jaishankar; Katherine Pontarolo-Maag; Jonathan M Eby; Steven W Henning; Yekaterina O Ostapchuk; Kettil Cedercreutz; Alpamys Issanov; Shikhar Mehrotra; Andreas Overbeck; Richard P Junghans; Joseph R Leventhal; I Caroline Le Poole
Journal:  Front Immunol       Date:  2020-12-01       Impact factor: 7.561

7.  B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma.

Authors:  Cheng Long; Gaowei Li; Chengyun Zhang; Tao Jiang; Yanjun Li; Xin Duan; Gang Zhong
Journal:  Front Oncol       Date:  2021-11-15       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.